PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY

PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY

Bibliographic Details
Main Authors:	Caterina Buquicchio, Jon Salmanton-García, Francesco Marchesi, Federico Itri, Caroline Besson, Sonia Martín-Pérez, Julio Dávila-Valls, Luana Fianchi, Laman Rahimli, Giuseppe Tarantini, Federica Irene Grifoni, Jorge Labrador, Raul Cordoba, Alberto Lopez-Garcia, Nicola Stefano Fracchiolla, Francesca Farina, Oliver A. Cornely, Livio Pagano
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000977036.45003.69

Similar Items

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
by: Francesco Marchesi, et al.
Published: (2023-04-01)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
by: Benjamin Chen, et al.
Published: (2023-01-01)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era.
by: Benjamin Chen, et al.
Published: (2023-01-01)

Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
by: Stefanie Dichtl, et al.
Published: (2022-09-01)

A case of prolonged COVID‐19 treated with tixagevimab/cilgavimab
by: Takahiro Shimizu, et al.
Published: (2023-03-01)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
by: Giulia Zamprogna, et al.
Published: (2023-05-01)

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
by: Olga Aleshina (Gavrilina), et al.
Published: (2023-08-01)

Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
by: Anna Gidari, et al.
Published: (2024-02-01)

Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19
by: Marina V. Zhuravleva, et al.
Published: (2023-02-01)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
by: Francesco Angotzi, et al.
Published: (2023-06-01)

Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients
by: Jowita Frączkiewicz, et al.
Published: (2024-03-01)

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA
by: I. Ntanasis-Stathopoulos, et al.
Published: (2023-05-01)

Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis
by: Luke B. Elias, et al.
Published: (2023-12-01)

Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
by: Karolina Akinosoglou, et al.
Published: (2022-12-01)

Experience with the combination of tixagevimab + cilgavimab for pre-exposure prophylaxis of COVID-19 in cancer patients: A retrospective analysis
by: Marina A. Lyadova, et al.
Published: (2023-12-01)

Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients
by: Roberta Angelico, et al.
Published: (2023-11-01)

The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis
by: Shaymaa Glhoom, et al.
Published: (2024-01-01)

Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis
by: Saad Alhumaid, et al.
Published: (2022-12-01)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
by: Daniele Focosi, et al.
Published: (2022-09-01)

Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study
by: Dejan Jakimovski, et al.
Published: (2023-02-01)

Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies
by: Anna A. Roppelt, et al.
Published: (2023-02-01)

Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection
by: Devika Sindu, MD, et al.
Published: (2023-06-01)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-09-01)

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
by: David Totschnig, et al.
Published: (2022-10-01)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
by: Daria S. Fomina, et al.
Published: (2023-10-01)

Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
by: Andrea Duminuco, et al.
Published: (2023-03-01)

Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data
by: Yinong Young-Xu, et al.
Published: (2023-08-01)

Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19
by: Nicolina Capoluongo, et al.
Published: (2023-10-01)

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial
by: F. D. Richard Hobbs, et al.
Published: (2024-02-01)

Necrotizing pancreatitis with invasive candidiasis and candidemia due to Candida albicans and pan-echinocandin-resistant Candida glabrata
by: Laman Rahimli, et al.
Published: (2024-03-01)

P1558: PROPHYLAXIS WITH TIXAGEVIMAB-CILGAVIMAB IN SINGLE-CENTER EXPERIENCE CAN REDUCE SEVERE COMPLICATIONS RELATED TO SARS-COV-2 INFECTION IN HEMATOLOGICAL PATIENTS
by: Andrea Duminuco, et al.
Published: (2023-08-01)

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)
by: Gustavo H. Kijak, et al.
Published: (2023-11-01)

Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients
by: Andrea Lombardi, et al.
Published: (2023-05-01)

Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.
by: Giovanni Manfredi Assanto ,, et al.
Published: (2023-10-01)

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
by: F. D. Richard Hobbs, et al.
Published: (2023-09-01)

Outpatient treatment with AZD7442 (tixagevimab/cilgavimab) prevented Covid-19 hospitalizations over 6 months and reduced symptom progression in the TACKLE randomized trial
by: Hobbs, FDR, et al.
Published: (2023)

Analysis of SARS-CoV-2 Emergent variants following AZD7442 (tixagevimab/cilgavimab) for early outpatient treatment of COVID-19 (TACKLE trial)
by: Kijak, GH, et al.
Published: (2023)

NIRMATRELVIR/RITONAVIR (NIRI) EM PACIENTES COM COVID-19 E MALIGNIDADES HEMATOLÓGICAS: RELATO DO EPICOVIDEHA (REGISTRO INTERNACIONAL ONLINE DE PACIENTES COM MALIGNIDADES HEMATOLÓGICAS, INFECTADOS POR SARS-COV-2)
by: Jon Salmanton-García, et al.
Published: (2023-10-01)

MELHOR DESFECHO CLÍNICO DA COVID-19 EM PACIENTES COM MALIGNIDADE HEMATOLÓGICA QUE RECEBERAM UMA QUARTA DOSE DA VACINA ANTI-SARS-COV-2: EPICOVIDEHA (REGISTRO INTERNACIONAL ONLINE DE PACIENTES COM MALIGNIDADES HEMATOLÓGICAS, INFECTADOS POR SARS-COV-2)
by: Jon Salmanton-Garcia, et al.
Published: (2023-10-01)

MOLNUPIRAVIR (MOL) COMPARADO A NIRMATRELVIR/RITONAVIR (NIRI) PARA COVID-19 EM PACIENTES DE ALTO RISCO COM MALIGNIDADE HEMATOLÓGICA NA EUROPA: UMA ANÁLISE PAREADA DO REGISTRO EPICOVIDEHA
by: Jon Salmanton-García, et al.
Published: (2023-10-01)